Strain Data Sheet

RBRC02661

Strain Information

Image
BRC No.RBRC02661
TypeCongenic
SpeciesMus musculus
Strain nameA.AKITA-Ins2<Akita>
Former Common nameAkita-Ins2 gene mutation congenic, A/J
H-2 Haplotype
ES Cell line
Background strainA
Appearance
Strain developmentDeveloped by Mitsuo Itakura, The University of Tokushima and Shigeru Takeshita, Astellas Pharm Inc. in 2005.
Strain description
Colony maintenance
References
A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse.
Wang J, Takeuchi T, Tanaka S, Kubo S K, Kayo T, Lu D, Takata K, Koizumi A, Izumi T
Journal of Clinical Investigation, 103, 27 (1999). 9884331

Diabetic modifier QTLs identified in F2 intercrosses between Akita and A/J mice.
Takeshita S, Moritani M, Kunika K, Inoue H, Itakura M
Mamm. Genome, 17, 927-940 (2006). 16964447

Health Report

Examination Date / Room / Rack

Gene

Gene SymbolGene NameChr.Allele SymbolAllele NameCommon NamesPromoterDiseases Related to This Gene
Ins2
MGI:96573		insulin II7Ins2 Akita
  • diabetes mellitus, permanent neonatal 4(MedGEN)

  • hyperproinsulinemia(MedGEN)

  • maturity-onset diabetes of the young type 10(MedGEN)
    • more 3 Diseases
  • maturity-onset diabetes of the young(DisGeNET)

  • permanent neonatal diabetes mellitus(DisGeNET)

  • type 1 diabetes mellitus 2(MedGEN)

    • Phenotype

    Annotation by Mammalian phenotyhpe ontology
  • abnormal Leydig cell morphology(MP:0002786)

  • abnormal adipocyte glucose uptake(MP:0004185)

  • abnormal adipose tissue amount(MP:0005452)

  • abnormal astrocyte morphology(MP:0002182)

  • abnormal cardiac muscle contractility(MP:0002972)
    • more 73 phenotypes
  • abnormal drinking behavior(MP:0001422)

  • abnormal glomerular capillary morphology(MP:0011320)

  • abnormal glucose homeostasis(MP:0002078)

  • abnormal heart left ventricle morphology(MP:0003921)

  • abnormal heart morphology(MP:0000266)

  • abnormal kidney interstitium morphology(MP:0011425)

  • abnormal microglial cell morphology(MP:0000136)

  • abnormal mitochondrial morphology(MP:0006035)

  • abnormal mitochondrial physiology(MP:0006036)

  • abnormal muscle cell glucose uptake(MP:0004130)

  • abnormal pancreas physiology(MP:0002693)

  • abnormal pancreatic alpha cell morphology(MP:0005216)

  • abnormal pancreatic beta cell mass(MP:0009112)

  • abnormal pancreatic beta cell morphology(MP:0005217)

  • abnormal pancreatic islet cell apoptosis(MP:0009488)

  • abnormal pancreatic islet morphology(MP:0005215)

  • abnormal renal glomerulus morphology(MP:0005325)

  • abnormal response to transplant(MP:0005671)

  • abnormal retina apoptosis(MP:0006072)

  • abnormal retina ganglion layer morphology(MP:0005241)

  • abnormal retina neuronal layer morphology(MP:0006069)

  • abnormal retina vasculature morphology(MP:0002792)

  • akinesia(MP:0002690)

  • albuminuria(MP:0002871)

  • decreased adipocyte glucose uptake(MP:0030017)

  • decreased body fat mass(MP:0014143)

  • decreased body weight(MP:0001262)

  • decreased bone mineral density(MP:0000063)

  • decreased circulating insulin level(MP:0002727)

  • decreased circulating leptin level(MP:0005668)

  • decreased circulating triglyceride level(MP:0002644)

  • decreased insulin secretion(MP:0003059)

  • decreased liver triglyceride level(MP:0009356)

  • decreased locomotor activity(MP:0001402)

  • decreased muscle cell glucose uptake(MP:0030022)

  • decreased pancreatic beta cell mass(MP:0009114)

  • decreased respiratory quotient(MP:0010379)

  • decreased subcutaneous adipose tissue amount(MP:0008844)

  • decreased triglyceride level(MP:0005318)

  • degranulated pancreatic beta cells(MP:0009255)

  • expanded mesangial matrix(MP:0011353)

  • glomerulosclerosis(MP:0005264)

  • heart left ventricle hypertrophy(MP:0002625)

  • hematoma(MP:0008817)

  • homeostasis/metabolism phenotype(MP:0005376)

  • hydronephrosis(MP:0000519)

  • hyperglycemia(MP:0001559)

  • impaired glucose tolerance(MP:0005293)

  • increased adipocyte glucose uptake(MP:0030016)

  • increased anxiety-related response(MP:0001363)

  • increased carbon dioxide production(MP:0008963)

  • increased energy expenditure(MP:0004889)

  • increased fluid intake(MP:0011941)

  • increased food intake(MP:0011939)

  • increased insulin sensitivity(MP:0002891)

  • increased leukocyte cell number(MP:0000218)

  • increased oxygen consumption(MP:0005289)

  • increased pancreatic islet cell apoptosis(MP:0014121)

  • increased renal glomerular filtration rate(MP:0005527)

  • increased renal glomerulus basement membrane thickness(MP:0011409)

  • increased retina apoptosis(MP:0030005)

  • increased vascular permeability(MP:0003070)

  • insulin resistance(MP:0005331)

  • kyphosis(MP:0000160)

  • polydipsia(MP:0001426)

  • polyphagia(MP:0001433)

  • polyuria(MP:0001762)

  • postnatal growth retardation(MP:0001732)

  • postnatal lethality(MP:0002082)

  • premature death(MP:0002083)

  • renal glomerular protein deposits(MP:0020518)

  • small pancreatic islets(MP:0009172)

  • thick interventricular septum(MP:0010724)
    • Detailed phenotype data

    Ordering Information

    Donor DNA
    Research applicationDiabetes and Obesity Research
    covid19_progression
    Specific Term and ConditionsIn publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Takeshita et al., Mammalian Genome, 17, 927-940 (2006). Takeshita et al., Mammalian Genome, under submissionThe RECIPIENT of BIOLOGICAL resource shall obtain a prior written consent on use of it from the DEPOSITOR Dr. Mitsuo Itakura, Institute for Genome Research, The University of Tokushima. The RECIPIENT must send a copy of the APPROVAL FORM approved by Dr. Mitsuo Itakura to Phamacology Research Labs, Astellas Pharma Inc. (Mr. Shigeru Takeshita) by fax (+81-29-847-1536) immediately, and then send it by mail. The RECIPIENT shall obtain a license from the DEPOSITOR in the case of application for any patents or commercial use with the reslts from the use of the BIOLOGICAL RESOURCE.
    DepositorAstellas Pharma Inc. and Tokushima University (Astellas Pharma Inc., Tokushima University)
    Strain Statusan icon for Frozen embryosFrozen embryos
    an icon for Frozen spermFrozen sperm
    Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
    Cryopreserved sperm (within 1 month)
    Cryopreserved embryos (within 1 month)
    Additional Info.Necessary documents for ordering:
    1. Approval form (Japanese / English)
    2. Order form (Japanese / English)
    3. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)

    Genotyping protocol -PCR-

    BRC mice in Publications

    No Data